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Abstract Asthma andrhinitis frequentlycoexist in allergic patients, butnasal symptomsmaypredominate, leading to
asthmaunderdiagnosis andundertreatment.Discriminant analysis obtains the bestdifferentiationbetweengroupsusing
one or one setof variables.Our aimwas to identify the laboratory test [allergen exposure, total and specific serum IgE,
lung function, blood eosinophils and, bronchialresponse and sensitivity tomethacholine (Mth) and allergen] or combina-
tionofthemthat allowedthebestdifferentiationbetweenmild asthma andallergic rhinitis.Across-sectional analysiswas
performedin 86Dermatophagoides pteronyssinus allergicrhinitispatients, whowere classified according to clinicaldata as
rhinitisplusmildasthma (n= 62) or‘‘pure’’rhinitis (n= 24).Bronchial symptomshadbeenexhaustivelyevaluatedduringa 2-
yearspre-inclusionperiod.Patientsunderwent skintests andbronchialchallengewithMth andallergen.The exposureto
D. pteronyssinus allergen (Der p1) was quantified in dust samples.Dose^response curveswith Mth [until the FEV1fell by
40% or themaximaldose (200mg/ml)wasinhaled]were attained.Wedevelopedmultiplemodelsofdiscriminant analysis
in order to evaluate the capacity of the above variables to differentiate groups. Asthma patients had higher total and
specific IgE levels and a greater sensitivity (PD20 values) and response [dose^response slope (DRS)] to both Mth and
allergen.Themodel entering these variableswas the one thatcorrectly classifiedmore patients (79.2%).The discrimina-
tivepowerofthemodelthatonlyincludedMth-DRSvalueswas similar tothe above (78.8%).BronchialresponsetoMthis
quantitatively different in allergic rhinitis patientswho displaymild asthma symptomswhen compared to those thatonly
report rhinitis, suggesting a distinct bronchial intrinsic behavior.The utilization of complete dose^response curveswith
Mth allows agood separationbetweenmild asthma and‘‘pure’’rhinitispatients andmightbeusefulinthe diagnosis ofmild
asthma.Whether the earlydetection and treatmentof these patients prevents the developmentof symptomatic asthma
needs further evaluation.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Asthma and rhinitis frequently coexist in atopic
patients. Rhinitis often precedes the onset of bronchial
symptoms and is considered an independent risk factor
for asthma(1).Rhinitis patients’ bronchial airways exhibit
changes (eosinophilic in¢ltration and activation,
subepithelial ¢brosis and epithelial cell shedding) similar
to those described in asthmatics (2^4). In rhinitis pa-
tients, natural (5) or experimental (6^8) exposure to
the allergen enhances bronchial hyperresponsivenessReceived 5 November 2001, accepted in revised form1July 2002
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Servicio de Alergolog|¤a,CS Conde Oliveto, Plaza de la Paz SN, 31002
Pamplona, Spain.Fax: +34 948 429271;
E-mail: jmolaguibel@telefonica.net(BHR) and eosinophilic in£ammation, resembling the
asthmatic response. Further, the isolated treatment of
rhinitis indirectly improves asthma symptoms and de-
creases BHR (9). These data suggest a common patho-
physiologic origin of both conditions and the lack of a
clear di¡erentiation between them.Factors determining
that subjects develop asthma or only rhinitis are far from
clear.
The bene¢t of early anti-in£ammatory treatment in
asthma has been documented (10).Due to the low sensi-
tivities of both, lung-function and biochemical tests (11),
the early detection of mild asthma patients is trouble-
some and often lies in clinical history (recurrent episodes
of airway narrowing) (12). The highly variable individual
perception of these episodes (13) can lead to a serious
underdiagnosis of the disease (14). In some instances,
ALLERGICRHINITISANDASTHMA 31the allergen-bronchial provocation test (A-BPT), a valu-
able model for the study of allergic asthma (AA) patho-
genesis, has been considered the ‘‘gold standard’’ in the
diagnosis of the disease (15). But rhinitis patients, who
have never experienced asthma symptoms, can posi-
tively respond to A-BPT (6,7) which questions the capa-
city of such tests to di¡erentiate both conditions.
We selected Dermatophagoides pteronyssinus mono-
sensitized patients who, in order to be accurately classi-
¢ed in the groups of ‘‘rhinitis andmild asthma’’ and ‘‘pure
rhinitis,’’ had been evaluated during a pre-inclusion peri-
od of 3 years. Multiple models of discriminant analysis
were developed in order to test the capacity of di¡erent
asthma-associated variables [lung function, allergen ex-
posure, eosinophils, total and speci¢c IgE and, bronchial
response to methacholine (Mth) and allergen] to sepa-
rate patients displayingmild asthma from those only re-
porting upper airway symptoms.
PATIENTSANDMETHODS
Patients and study design
We recruited 86 non-smoking D. pteronyssinus- mono-
sensitized patients who had been evaluated for a 3-year
period (median); interquartile range (IQR): 2^4 years.
During this time, bronchial symptoms (recurrent attacks
of wheezing, cough, breathlessness and chest tightness)
(16) had been repeatedly interrogated. Patients were
then classi¢ed as ‘‘mild asthma and rhinitis’’ (n=62) and
‘‘pure rhinitis’’ (n=24).Only short-acting b-agonist drugs
used ‘‘as needed’’were allowed in the previous 2months.
The selection of patients was not carried out according
to the presence of BHR. No subject had su¡ered from
lower or upper respiratory tract infections or had been
treated with oral or inhaled corticosteroids within the
preceding 2 months. Dermatophagoides pteronyssinus al-
lergy was established by positive skin-prick tests and
speci¢c IgE to this allergen, in the context of a compati-
ble clinical history. Patients sensitized to other allergens
were excluded.
Once patients were grouped, the study was carried
out over 2 consecutive days. First, patients underwent
clinical and physical evaluation, venous blood was
sampled, skin tests and themethacholine-bronchial pro-
vocation tests (Mth-BPTs) were done and, dust from pa-
tients’ beds was collected. The A-BPT was performed
the following day. Informed written consent was ob-
tained from all patients before starting the study. The
ethics committee of our hospital approved the study
protocol.
Allergen extract
Anextract ofD. pteronyssinus partiallypuri¢ed andbiolo-
gically standardizedwas used for skin andbronchial chal-lenge tests (ALK-Abello¤ , Spain). Speci¢c monoclonal
antibodies were used to quantify the major mite aller-
gens (Der p1and Der 2) (17).The ¢nal extract at100bio-
logic units (BU)/ml contained 40mg/ml of Der p 1 and
20mg/ml of Der 2.
METHODS
Collection of dust samples and quantitation
ofmite allergens
Dust collection was carried out 7 days after the last
cleaning, as previously described(18). A portable vacuum
cleaner provided with a pre¢lter (ALK, Denmark) was
used(19). After vacuuming, the ¢lter box was removed
and stored at 201C until further analysis. The content
ofDer p1allergenwas determined in duplicate by a com-
mercial enzyme-linked immunosorbent assay (ELISA)
based onmonoclonal antibodies (ALK-Abello¤ . Denmark)
(17).
Skin tests
Skin-prick tests were carried out with a standard bat-
tery that included the most common airborne allergens
in our area (mites, pollens, molds, and animal dander)
(ALK-Abello¤ , Spain) (20).We also tested theD.pteronyssi-
nus extract (containing 50% glycerin, 0.4% phenol, and
0.9% NaCl) at three concentrations (60, 12, and 2.4mg/
ml of Der p 1) in duplicate and in the inverse direction.
The resulting wheals were shaped and transferred to a
millimeter-squared paper, where areas were measured
and expressed in millimeters squared. We considered
for analysis the mean value of the skin areas obtained
from the six tests.
Bronchial provocation tests
Every lung-function test was performed with the same
spirometer (model CPR, Medical Graphics inc. St Paul,
MN, U.S.A.). Spirometry (21) and BPTs (22) were made
according to international guidelines. Reference values
of Crapo et al. (23) were used. Mth or allergen extract
was administered by a dosimeter (MEFAR s.r.l.; MEFAR,
Borezzo, Italy), programmed to deliver ¢ve inhalations of
1s each.Patientswere instructed to take slow vital-capa-
city inhalations and,10ml of solutionwas administered in
each breath. Before starting the BPTs, patients inhaled
diluent (PBS), and variability lower than 5% between
baseline and postdiluent FEV1values was required.
Methacholine-BPT
To avoid the circadian rhythme¡ect on airwaydynamics,
Mth-BPTswere done between 2 and 4 P.M.Methacholine
TABLE 1. Patients demographic characteristics (median
and interquartile range: IQR)
AR AA
N 24 62
Sex 16 male (66.7%) 40 male (64.5%)
Age (years) 21 (IQR:18^23) 20 (IQR:18^29)
Duration of
asthma (years)
F 2.0 (IQR:1.0^4.25)
Abbreviations:AA: allergic asthma;AR: allergicrhinitis.
32 RESPIRATORYMEDICINE(Provocholine, Roche Laboratory. Nutley, NJ, U.S.A.) at
serially increasing concentrations (0.125, 0.25, 0.5, 1.0,
2.0, 5.0, 10.0, 25.0, 50.0, 100.0, and 200.0mg/ml in PBS)
was administered by the MEFAR dosimeter, and the
FEV1value was measured by spirometry 3min later.The
test ¢nishedwhen a fall in FEV1values equal to or higher
than 40% from the postdiluent value was achieved, or
when the highest concentration was inhaled. Results
were expressed in terms of the Mth-PD20 [provocative
cumulative dose of Mth in mmol (1mol Mth=195.4 g)
needed to decrease FEV1by 20% from thepostdiluent va-
lue), and the dose^response slope (Mth-DRS): percen-
tage of change in FEV1 from the postdiluent values in
response to the cumulative dose of Mth inhaled (24).
Allergen-BPT
Every A-BPTwas done between 8 and 10 A.M. The D.
pteronyssinus extract at increasing concentrations (0.04,
0.1, 0.2, 0.4,1.0, 2.0 and, 4.0ng Der p1/ml in PBS) was ad-
ministered by the MEFAR dosimeter, and FEV1 values
were recorded10min later.The test ¢nished when a fall
in FEV1values equal to or higher than 20% of the postdi-
luent valuewas achieved or when the highest concentra-
tion of allergen was inhaled. Results were expressed in
terms of the A-PD20 [provocative cumulative dose of al-
lergen (in ng of Der p1] needed to decrease FEV1by 20%
of the postdiluent values] and the dose^response slope
(A-DRS) (percentage of change in FEV1 from the postdi-
luent values in response to cumulative dose of allergen
inhaled).
Measurements in peripheral blood
Total numbers of eosinophils were quanti¢ed in blood.
Total and D. pteronyssinus speci¢c serum IgE were deter-
mined with a £uoro-enzyme immunosorbent assay
(UNICAP. Pharmacia Diagnostics, Uppsala, Sweden).
The limits of detection for the £uid-phase assays were
2kU/l for total IgE and 0.35kU/l for speci¢c IgE.
Statistical analysis
Statistical analysis of the datawas performedusing a sta-
tistics program (SPSS Windows 9.0; SPSS; Chicago, IL).
Descriptive statistics were used to summarize the clini-
cal and demographic characteristics of the patients. Log
transformation was used to obtain normal distribution
of data.Comparative analysis of means was carried out
by the analysis of variance (t-test for equality of means).
Correlation among variables was analyzed with the
Pearson’rankcorrelation coe⁄cient.We developedmul-
tiple models of discriminant analysis, by entering in step
and in non-step fashion all the log-transformedvariables.
Our criterion for variable selection was the minimiza-tion of Wilks’ lambda method. At each step, the variable
that resulted in the smallestWilks’ lambda for the discri-
minant analysis was entered. The selection of variables
was made according to the following criteria: Wilks’
lambda: 0.623, maximum number of steps 20, minimum
tolerance level 0.001,minimum F to enter 3.84,maximum
F to enter 2.71. A P value ofo0.05 was considered signif-
icant.
RESULTS
Tables 1 and 2 exhibit the demographic, immunological
and lung-functional data by group classi¢cation. Total
and speci¢c serum IgE levels were higher in the asthma
group (Table 2). All thepatients underwentMth-BPT but
three subjects from the rhinitis group and six from the
mild asthma group did not consent to undergo the A-
BPT. The Mth-BPT results from one patient included in
the AA group were not analyzed since his spirometry
maneuvers were not reproducible. Mth and A-challenge
were tolerated without complication and Mth- and A-
PD20 values were obtained in every asthma patient and
in16 and 20 rhinitis patients, respectively.Groups statis-
tically di¡ered in PD20 and DRS values to both, Mth and
allergen (Table 2). In the asthma group and in the whole
sample, thevalues ofMth- andA-DRS correlatedwithA-
PD20 values and, with total and speci¢c serum IgE levels
(Table 3). Adegree of associationwas observedbetween
Mth-DRS values and blood eosinophilia in both groups
(Table 3). Only in the asthma group, the exposure to
Der p 1 allergen correlated with the values of Mth-DRS
and A-DRS (Table 3).
We developedmultiplemodels of discriminant analysis
by including in step or non-step fashion all the variables.
Themodel that showed thehighestdiscriminativepower
(WilksŁ lambda: 0.623, Po0.0001) was the one that ana-
lyzed in a stepwise fashion the levels of total and speci¢c
serum IgE and the values of Mth- and A-DRS. Mth-DRS
was the variable that exhibited the highest contribution
to the discriminant function (Table 4). The overall per-
centage of cases correctly classi¢ed with this model
(Table 5) was 79.2 % (61out of the 77 patients).Mth-DRS
was the ¢rst variable included in the stepwise analysis
TABLE 2. Allergenexposure, sensitization, andlung functionindicesinrhinitis (AR) andasthma (AA) groups (geometricmeans
andgeometric standard deviation).Comparative analysis between groups (t-test for equalityofmeans)
AR AA Signi¢cance
Der p1levels (mg/gdust) 3.157 6.76 1.9077.76 NS
Skintests (mm2) 53.7071.98 70.3071.60 NS
Blood eosinophils (cell/mm3) 331.1371.79 338.8471.90 NS
Total serum IgE (kU/l) 114.8073.02 239.8872.60 P= 0.003
Speci¢c serum IgE (kU/l) 17.7872.95 39.8072.09 Po0.001
Baseline FEV1 (%) 104.7171.09 100.0271.12 NS
Mth-PD20 (mmol) 28.8479.12 1.9077.76 Po0.001
Mth-DRS (%/mmol) 0.4375.49 5.107 8,43 Po0.001
A-PD20 (ng Der p1) 14.127 3.47 5.2173.55 P= 0.003
A-DRS (%/ng Der p1) 0.747 4.46 3.4373.80 Po0.001
Abbreviations:NS: not signi¢cant;Mth-PD20: methacholine-PD20 values;Mth-DRS: methacholine dose^response slope; A-
PD20: allergen-PD20 values; A-DRS: allergen dose^response slope.
TABLE 3. Correlation among variables in the asthma (AA) group and in the whole sample (WS) (Pearson’ rank correlation
coe⁄cient).
Derp1 ST t-IgE s-IgE Eosinop. Mth-DRS A-PD20 A-DRS
Mth-DRS AA P= 0.013 F P= 0.005 P = 0.065 P = 0.038 Po0.001 Po0.001
r= 0.46 F r= 0.38 r = 0.25 r= 0.30 r=0.57 r = 0.58
WS F F Po0.001 P= 0.001 P= 0.036 Po0.001 Po0.001
r= 0.45 r= 0.35 r= 0.36 r=0.53 r= 0.58
A-DRS AA P= 0.037 F P= 0.005 P= 0.045 F Po0.001 Po0.001
r= 0.39 F r= 0.38 r= 0.27 r= 0.58 r=0.90
WS F Po0.001 Po0.001 F Po0.001 Po0.001
r= 0.50 r= 0.50 r= 0.58 r=0.91
Abbreviations: ST: skintests; t-IgE: total serum IgE; s-IgE: speci¢c serum IgE.
TABLE 4. Standardized discriminant functions coe⁄-
cients and pooled within-groups correlations (structure
matrix)
Variable Standardized
coe⁄cients
Structurematrix
coe⁄cientsa
Functionb
Mth-DRS 0.765 0.897 1.000
A-DRS 0.298 0.728 0.467
t-IgE 0.272 0.439 0.343
s-IgE 0.432 0.501 0.200
Abbreviations: Mth-DRS: methacholine dose^re-
sponse slope; A-DRS: Allergen dose^response slope; t-
IgE: total serum IgE; s-IgE: speci¢c serum IgE.
aThe structure matrix coe⁄cients represent the pooled
within-groups Pearson’correlation coe⁄cients between
the discriminant function and the originalvariables.
b ‘‘Function’’ displays the pooled within-group Pearson’
correlationsbetween discriminant variables and thetypi-
¢ed canonic discriminant function.
ALLERGICRHINITISANDASTHMA 33and, at this point, the model (Wilks’ lambda: 0.672,
Po0.0001) correctly classi¢ed 78.8% of the cases (Table
6). These results were very similar to those obtained
with the ¢rst model that also entered A-DRS and total
and speci¢c serum IgE (Table 5).
DISCUSSION
Pathogenic and epidemiological data suggest that asthma
and rhinitis are linked conditions (2,7). Asthma develop-
ment is associated with atopic family constitution and
perennial indoor allergen exposure during the ¢rst years
of life (25).Mites (D. pteronyssinus) are themost common
indoor allergens in nearly all the world (18), but the rea-
son why some mite-allergic patients develop asthma
whereas others only present nasal symptoms is poorly
understood. Several tests including exposure and sensiti-
zation to the allergen, blood eosinophils or lung-function
tests with either bronchoconstricting agents or allergen
TABLE 5. Resume table for diagnosis classi¢cation ob-
tainedwiththemodel that entered total and speci¢c ser-
um IgE,Mth-DRS and A-DRSvalues
Observed Predicted Total
AR AA
AR 18 (85.7%) 3 (14.3%) 21
AA 13 (23.2%) 43 (76.8%) 56
Overall: 79.2%
Thismodelcorrectlyclassi¢ed the 79.2% ofthe original
cases.
Abbreviations: AR: allergic rhinitis; AA: allergic asthma.
TABLE 6. Resume table for diagnosis classi¢cation ob-
tainedwiththemodel thatonlyentered Mth-DRSvalues
Observed Predicted Total
AR AA
AR 21 (87.5%) 3 (12.5%) 24
AA 15 (24.6%) 46 (75.4%) 61
Overall: 78.8%
Thismodelcorrectlyclassi¢edthe 78.8% ofthe original
cases.
Abbreviations: AR: allergic rhinitis; AA: allergic asthma.
34 RESPIRATORYMEDICINEare often utilized in the evaluation of allergic asthma. In
this study, mite-monosensitive patients were recruited
and classi¢ed as mild asthma or rhinitis on the basis of
an exhaustive clinical history that was our ‘‘gold stan-
dard’’ to confront groups. All the patients had been eval-
uated for at least 2 years and bronchial symptoms had
been repeatedly discarded in the rhinitis group.We con-
ducted severalmodels of discriminant analysis to identify
the laboratory test or combination of them that allowed
the best di¡erentiation between groups.
The absence of asthma symptoms in some patients
presenting BHRhasbeen attributed to an insu⁄cient sti-
mulus to cause symptomatic airway narrowing (26). Sup-
porting such hypothesis, a moderate association
between Der p 1 allergen exposure on the one hand
and, sputum mast cell activation and asthma symptoms
on the other was observed in AA (27). Further, higher
exposure to Der p 1 was described among asthma pa-
tients displaying late pulmonary responses following A-
BPTs (8). In this study and exclusively in the asthma
group, Der p 1 exposure correlated with Mth- and A-
DRS values. However, patients reporting asthma symp-
toms were not exposed to higher levels of Der p1 aller-
gen. Such ¢nding is in keeping with other reports (28)
and suggests that other factors (bronchial intrinsic dy-namics, severity of the immunological response) should
be implied in asthma presentation. As reported (29),
asthma patients exhibited higher levels of total and spe-
ci¢c IgEwhat suggests a more intense systemic immuno-
logical response to the allergen among subjects
exhibiting asthma symptoms.
BHR is a complex functional disorder of the airways
de¢ned by dose^response curves that provide di¡erent
information (30). The shift of the curve to the left indi-
cates increased sensitivity and is mainly dependent on
the loss of integrity of the respiratory epithelium (31).
The severity of the response, given by a steeper DRS
and either, the lack of identi¢cation of a maximal airway
narrowing plateau or its detection at high degrees of air-
way obstruction, is presumably the most important
asthma functional feature since it puts subjects at risk
for serious disease (30). Bronchial response is due to
both, the reduction in the forces that limit airway nar-
rowing and the increase in airway wall thickness (31,32).
All of them, in£ammatory in¢ltrate, edema of the sub-
mucosa anddeposition of collagen in the epithelial subba-
sementmembrane can increase bronchial wall thickness
and enhance the response to the agonist. Eosinophils,
through the release of tumor growth factor-b1, are likely
implied in the deposition of collagen in the epithelial sub-
basement membrane and, a close relationship between
ongoing eosinophilia and bronchial structural changes
has been proposed (33). Accordingly, we observed a
weak correlation among blood eosinophils and Mth-
DRSvalues.The lackof di¡erences in eosinophil numbers
between groupsmightbe explained since theirmeasure-
ment inbloodmightnotbe representative enough of the
immunological response occurring at the airways (4).
Although at a lesser extent than patients displaying asth-
ma symptoms, a considerable percentage of rhinitis sub-
jects exhibited a positive response to Mth and allergen
(PD20 values were recorded).
Discriminant analysis mathematically obtains the best
di¡erentiation among groups of subjects using one or
one set of variables (34).The model exhibiting the high-
est discriminative capacity (rightly diagnosed 80% of the
patients) was the one that entered total and speci¢c ser-
um IgE, Mth-DRS and A-DRS, and confronted them to
the clinical diagnosis. The lower discriminative power of
both Mth-and A-PD20 values compared to their corre-
sponding DRS values is attributable to the di¡erent me-
chanisms underlying bronchial sensitivity and response
(30), as well as to the utilization of arbitrary data since
PD20 values were not identi¢ed in every rhinitis patient.
It is remarkable that the discriminative power of the
model was not increased by the introduction of any
other variable than Mth-DRS (entered in the ¢rst step),
which strongly suggests that most of its discriminative
capacity is monopolized by this variable.The higher dis-
criminatory power of Mth-DRS values compared to the
corresponding A-DRS values might be imputed to the
ALLERGICRHINITISANDASTHMA 35di¡erent FEV1drops induced in both challenges. Since in
the Mth-challenge we induced FEV1 drops by 40% [safe
andwell tolerated in asthmatics (35)], due to ethical rea-
sons and to avoid the possibility of severe late asthmatic
response (36) in the allergen challenge, only FEV1 falls by
20% were induced.
To summarize, the major di¡erence between mild
asthma andrhinitis lies in the intrinsic behavior of the air-
ways and, the index that best di¡erentiates both condi-
tions is the slope of the dose^response curve obtained
with Mth.The increase in bronchial wall thickness would
lead to exaggerated airway narrowing when the smooth
muscle shortens and then to a steeper slope of the
dose^response curve. In£ammatory changes and col-
lagen deposits in the bronchial wall are features of asth-
ma but have also been described in rhinitis patients who
have never experienced bronchial symptoms (2,3). This
¢nding suggests thatother factors, secondary to the fail-
ure of the lungparenchyma to attenuatemuscle shorten-
ing, are implied in the development of asthma symptoms
(32). Due to the high prevalence of allergic rhinitis and
mild asthma, we are aware of the di⁄culty of including
complete dose^response curves to Mth in the initial
evaluation of these conditions. However, given the large
variability in the individual perception of airway narrow-
ing episodes (13), their evaluationmight allow a more ac-
curate diagnosis of patients with mild bronchial
symptoms who would bene¢t from early anti-in£amma-
tory treatment (10).Whether such measures might pre-
vent the development of chronic asthma should be
established by prospective studies.
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